Aflibercept, a decoy receptor and VEGF trap, was tested in a phase 2 trial of MDS and MDS/MPN overlap patients who have failed hypomethylating agents, and was also ultimately halted early due to lack of efficacy [14]. Here, VEGFA is linked to myeloproliferative disorder.